共查询到20条相似文献,搜索用时 78 毫秒
1.
2.
考察^131I-HAb18在正常人体内的生物学分布和器官辐射吸收剂量、为临床用提供必需的依据。一健康志愿者静脉给药后没时间用γ相机行全身及局部并采取血样本及留全尿,按医学内照射剂量纲要计算器官吸收剂量。 相似文献
3.
4.
5.
6.
7.
目的:对改良Mather氏法标记的大剂量 ̄(131)Ⅰ-HAb18McAb进行了临床前质量控制.方法:用常规检测方法(柱层析法、PAGE电泳法、体外培养细胞结合分析等)检测了三批样品的游离碘率、体外细胞免疫结合率、无菌、热原质及热稳定性实验等.结果:本法标记物样品热原质、无菌、毒性试验均合格, ̄[131]Ⅰ蛋白标记率≥88.3%,游离碘率≤12.6%,细胞免疫结合率>50%,白蛋白非特异标记率<6%,标记物在37℃48h内,游离碘释放率<20%,细胞免疫结合率>40%.结论:本法制备的碘标记物各项安全指标合格.热稳定实验提示超过48h的标记物游离碘及免疫活性变化较大. 相似文献
8.
本实验所用单抗Hepama Ⅰ(小鼠IgG_1)由细胞所提供,已作抗体专一性分析及鉴定,经MNTS-100自动纯化仪纯化,以Iodogen法将~(131)NaⅠ标记Hepama Ⅰ,Sephadex G-25分离游离碘,0.22μm滤膜过滤除菌,标记率1.85×10~8~2.59×10~8 Bq/mg,最终得无菌、无色透明的蛋白注射液。12例不能切除的巾晚期肝癌,均为男性,4例经开腹穿刺活检确诊为肝细胞癌:8例经临床诊断为原发性肝癌,诊断方法包括:血清AFP、B超、CT、ECT、MRI等。均为巨块型,未经任何治疗。注射前3d起口服Rugels液封闭甲状腺,注射前10min肌注地塞米松10mg。10例从肝动脉注入,2例经外周 相似文献
9.
1 材料和方法1.1 材料 1实验动物 :BAL B/c雌性小鼠 8wk龄 ,体质量18~ 2 0 g,购自本校实验动物中心 ;2组织细胞 :正常成人新鲜肝组织 ,肝癌组织取自本校外科手术标本 ,部分组织以中性福尔马林固定 ,低温石蜡包埋切片 ,4℃保存备用 .Sp2 /0细胞 ,肝癌细胞株 SMMC- 772 1,HHCC,He PG2由本室保存 ;3主要试剂 :HT,HAT选择培养基 RPMI16 40培养基购自Sigma公司 ,环磷酰胺注射液系连云港德瑞制药有限公司产品 ,Envision购自美国 DAKO公司 .1.2 方法 1正常成人肝组织于 2 0 0目镍网中研磨后 ,无菌生理盐水悬浮制成肝细胞悬液 … 相似文献
10.
131I标记抗CEA单抗预防人结肠癌肝转移的实验研究 总被引:5,自引:0,他引:5
目的 探索早期应用^131I标记惮朱癌肝转移的可行性。方法 在建立人结肠腺癌习肝转移后,于15min、10、20d经尾静注射^131I标记抗CEA单抗,于放射免疫疗法后4周和裸鼠死亡时,检查肝转移癌的数目、大小、瘤重、组织不和生存期。结果早期治疗组的肝转移癌数目、大小和瘤重均明显减小,瘤结节内有明显坏死,生存期延长。结论 早期应用^131I标记抗CEA单抗能有效地抑制肝转移癌的形成。 相似文献
11.
12.
~(131)I治疗甲亢经历了50多年的历史,治疗病人已超过100多万例。现公认~(131)I是一种简便、安全、经济、有效的甲亢治疗药物,其远期疗效高,复发率低,并发症少,目前已成为治疗甲亢的主要方法。甲亢用~(131)I治疗前要选择好适应证和禁忌症,确定适当的剂量,进行长期随访,密切注意早发、晚发甲状腺功能低下(甲低)的出现,并给予适当的治疗。 相似文献
13.
14.
15.
16.
17.
~(131)I治疗甲状腺功能亢进症的临床观察 总被引:1,自引:0,他引:1
目的:探讨131I治疗弥漫性甲状腺肿伴甲状腺功能亢进症的疗效。方法:对169例甲状腺功能亢进症患者采用131I治疗,并对疗效进行观察。结果:135例甲亢症状、体征消失,FT3、FT4、TSH正常;16例甲亢症状、体征部分消失,FT3、FT4、TSH有所下降,但仍高于正常;8例治疗无效,行手术治疗。治疗3月后亚临床甲低3例,患者无甲低症状和体征,6月后恢复正常。7例出现FT3、FT4低于正常,TSH高于正常,需长期服甲状腺素片替代治疗。结论:131I治疗弥漫性甲状腺肿伴甲状腺功能亢进症是有效、安全的治疗手段,但是对患者应随访。 相似文献
18.
Papillary carcinoma of the thyroid is the most common type of thyroid cancer and is associated with a good prognosis. Complications of treatment with surgery and radioiodine are uncommon. We report the case of a 13 year old boy who developed testicular damage following treatment with radioactive iodine 350 mCi for a papillary carcinoma of the thyroid. Four years after radioiodine treatment there has been no suggestion of recovery of spermatogenesis. Detailed follow-up studies of similarly treated young patients are required to define the incidence of this complication and to determine its reversibility. 相似文献
19.
20.
Context In May 1997, the US Nuclear Regulatory Commission (NRC) revised its patient release regulations, allowing for outpatient administration of larger activities of sodium iodide 131I than previously permitted. Objective To measure the radiation exposure to household members from patients receiving outpatient 131I therapy for thyroid carcinoma in accordance with the new regulations. Design Consecutive case series from October 1998 to June 1999. Setting and Patients Thirty patients who received outpatient 131I therapy following thyroidectomy for differentiated thyroid carcinoma were enrolled, along with their 65 household members and 17 household pets. Main Outcome Measure Radiation exposure to household members and 4 rooms in each home, as monitored with dosimeters for 10 days following 131I administration. Results The patients received 131I doses ranging from 2.8 to 5.6 GBq (mean, 4.3 GBq). The radiation dose to 65 household members ranged from 0.01 mSv to 1.09 mSv (mean, 0.24 mSv). The dose to 17 household pets ranged from 0.02 mSv to 1.11 mSv (mean, 0.37 mSv). The mean dose to the 4 rooms ranged from 0.17 mSv (kitchen) to 0.58 mSv (bedroom). Conclusion In our study, 131I doses to household members of patients receiving outpatient 131I therapy were well below the limit (5.0 mSv) mandated by current NRC regulations. 相似文献